Ixaka, In vivo Car-T Cells

Ixaka est une société de thérapie cellulaire et génique axée sur le pouvoir naturel du corps à guérir les maladies. Dans cette vidéo, ils souhaitaient présenter leur technologie innovante autour de nanoparticules, qui stimulent le système immunitaire du patient pour éliminer les cellules cancéreuses en renforçant les défenses de l’organisme, contrairement aux chimiothérapies qui attaquent directement les cellules cancéreuses.


Car-T Cells are T-Cells removed from the body of a cancer patient and genetically modified to strengthen their tumor targeting abilities. Once readministered, Car T-Cells enhance the immune response to cancer.

Car T-Cells have led to remarkable results in cancer patients and the chances of recovery, but there are several challenges associated with the traditional Car T approach. The process, technology and level of skill and expertise required to manufacture traditional tailor-made Car T-Cells means that it is a high cost and resource heavy therapy.

For each cancer patient, blood samples are frozen and transported to a dedicated GMP production site. There, the T-Cells are isolated, genetically modified and incubated for several weeks, before being returned for readministration into the patient.

Safety is a concern, as Car T-cells can induce and uncontrolled immune response, that is too strong for the patient. Misdosing can even lead to the patients death.

To address these challenges, the biotech company Ixaka is working to develop In-vivo Car T-Cells, which are T-Cells genetically modified directly within the patient, removing the costly manufacturing process and improving safety.

The in-vivo Car T-Cells use Ixaka’s targeted nanoparticle technology, consisting of nanoparticles encapsulating a lentiviral vector. Once injected into the patient, the nanoparticles specifically target T-Cells. They deliver the lentiviral vector, which modifies the T-Cells to express a universal Car receptor, enabling the newly formed Car T-Cells, to bridge to tumor cells, to kill them.

By applying their T&P development program in this way, the Ixaka team aims to claim clinical proof, that nanoparticles can successfully target and modify T-Cells directly within the patient.

This approach promises to be cheaper, safer, more effective and more adaptable for each individual patient.